BOUKJE.COM CONSULTING BV

Their core work

Boukje.com Consulting is a Dutch SME that provides specialized consulting and project management services to EU-funded research consortia across highly diverse technical domains. Rather than offering deep expertise in a single field, they appear to contribute project coordination support, dissemination, exploitation planning, or business development services — enabling research teams to maximize the impact and reach of their results. Their project portfolio spans solar photovoltaics, advanced materials, and cancer immunotherapy, which strongly suggests a cross-cutting consulting role rather than domain-specific R&D.

What they specialise in

How they've shifted over time

BCC started in the manufacturing and industrial sustainability space (2015-2018), working on solar factory efficiency and advanced tooling materials. From 2021 onward, they made a striking pivot into biomedical research, joining a cancer immunotherapy project focused on microfluidics and T-cell therapies. This trajectory suggests a consultancy that follows opportunity and impact potential rather than building depth in one technical silo — their value lies in transferable project skills, not domain lock-in.

BCC is moving toward life sciences and health, suggesting future collaborations will likely be in biotech, medtech, or personalized medicine rather than their earlier industrial focus.

How they like to work

BCC always joins as a participant, never leading consortia — consistent with a consulting SME that provides supporting services to research-driven partnerships. With 27 unique partners across just 3 projects, they integrate into large, diverse consortia (averaging 9+ partners per project) rather than small focused teams. This pattern indicates they are comfortable operating in complex multi-partner environments and adapting to different technical cultures.

Despite only three projects, BCC has built a network spanning 27 partners across 12 countries, reflecting the large consortia they join. Their reach is solidly pan-European with no obvious geographic concentration beyond their Dutch home base.

What sets them apart

BCC's distinguishing feature is their willingness and ability to operate across radically different technical domains — from photovoltaic manufacturing to cancer immunotherapy — which is unusual for an SME. This makes them a flexible partner for consortia that need non-technical support functions (dissemination, exploitation, business planning) without sector restrictions. For consortium builders, they offer a proven track record of fitting into large RIA projects regardless of the technical subject matter.

Highlights from their portfolio

• INCITE
  Represents a major domain shift into cancer immunotherapy and 3D-printed microfluidics — their largest single grant (EUR 338,875) and most recent project.
• Flintstone2020
  Addressed the strategic EU priority of reducing dependence on critical raw materials like tungsten in industrial tooling, with EUR 308,000 in funding.